Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076975 | 0.97 | S1PR1 (0.34) | S1PR1S1PR3S1PR5CTSSCTSB | |
| SCHEMBL7078195 | 0.96 | S1PR1 (0.36) | S1PR1S1PR3S1PR5CTSSCTSB | |
| SCHEMBL5357547 | 0.93 | CTSS (0.33) | CTSSCTSBCTSKCTSL | |
| SCHEMBL5357508 | 0.87 | CTSS (0.30) | CTSSCTSBCTSK | |
| SCHEMBL5368719 | 0.86 | CTSS (0.42) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4840213 | 0.83 | CTSS (0.34) | CTSSCTSBCTSKCTSL | |
| SCHEMBL5364136 | 0.83 | CTSS (0.32) | CTSSCTSBCTSKCTSL | |
| SCHEMBL5364012 | 0.83 | CTSS (0.36) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4840261 | 0.83 | CTSS (0.34) | CTSSCTSBCTSKCTSL | |
| SCHEMBL5366731 | 0.82 | CTSS (0.33) | CTSSCTSBCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | S1PR1 2783/4885S1PR3 3352/4885S1PR5 3824/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | S1PR1 2783/4885S1PR3 3352/4885S1PR5 3824/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | S1PR1 2783/4885S1PR3 3352/4885S1PR5 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.